Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Darae Law and IP Firm Metabolic Disease CNS Drug Development DELEGATE(S) Sangyong Yun, IP Consulting & Business Team, Senior Researcher Eui Kim, [email protected] 10th Floor KIPS Gangnam-Gu 135-080 Korea - South Korea www.daraelaw.co.kr Incorporated: 1999 Employees: 93 Ownership: Private MISSION/BACKGROUND Darae is the first technology transaction specialization firm in South Korea. We strategically approach every transaction in order to be tailored to meet client’s unique needs. To achieve successful technology transaction, we have an excellent strategy. Our strategy : Matching the right Fenwick & West experts to transactions — Corporate, Securities, Tax, Antitrust, IP, Benefits, Licensing and Litigation personnel will be consulted to optimally structure and negotiate the transaction. Integrated IP due-diligence that facilitates integration of acquired technologies, in-bound licenses and channel customer contracts. Experts remain involved as needed throughout the transaction and after closing to ensure efficient integration. Moreover, Darae has achieved the success of our clients by our effective knowledge-sharing teamwork. We assign a dedicated team of experts with in-depth knowledge of specific area of practice. We allocate the best people for each specific project. Our specialized team of experts consists of: Former judges of Patent Court, District Court and Supreme Court; examiners of Korea Intellectual Property Tribunal, Korea Intellectual Property Office and corporate patent experts. Finally, Darae is recognized in the industry and media for its excellence in the area of IP and technology transaction. Awarded Best IP Law Firm by Chambers & Partners (Asia) 2008 and 2009. TECHNOLOGY Our firm introduced KR-1-2 a competitive drug candidate for various diseases. KR-1-2 is a new chemical inhibitor of human 11beta HSD1. It can be a competitive drug candidate for type 2 diabetes, dementia and glaucoma. K-1-2 shows the prolonged and complete inhibition of 11 beta-HSD1 in both target tissues (fat & liver) and high potency and selectivity in humanized cells. KR-1-2 shows excellent DMPK profile: High metabolic stability; No CYP450 inhibition; Plasma protein binding & stability acceptable; Exellent PK profile. In addition, KR-1-2 shows good safety and toxicity profiles, therefore, KR-1-2 is a attractive drug candidate for type 2 diabetes, dementia and glaucoma. PRODUCTS Name Phase Indication Milestone KR-1-2 Preclinical Type 2 diabetes/glacuma/dementia Preclinical completed in 2011. Company Profiles – 13